3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Renal Cell
14
Neoplasms
6
Neoplasm Metastasis
6
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Hepatocellular
4
Triple Negative Breast Neoplasms
3
Sarcoma, Ewing
3
Ovarian Neoplasms
3
Melanoma
3
Kidney Neoplasms
3
Pancreatic Neoplasms
2
Osteosarcoma
2
Multiple Myeloma
2
Leukemia, Myeloid, Acute
2
Hematologic Neoplasms
2
HIV Infections
2
Endometrial Neoplasms
2
Carcinoma, Medullary
2
Breast Neoplasms
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Interventions
AZD 6244
2
pirfenidone
1
cabozantinib
1
Sorafenib
1
Pharmacokinetics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neurofibroma, Plexiform
×
cabozantinib
×
Clear all
NCT06502171
2026-03-12
NF113
University of Alabama at Birmingham
Phase 1
Not yet recruiting
30 enrolled